Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

被引：0
|
作者：
Samalin, E. [1 ]
Bouche, O. [2 ]
Thezenas, S. [1 ]
Francois, E. [3 ]
Adenis, A. [4 ]
Bennouna, J. [5 ]
Taieb, J. [6 ]
Desseigne, F. [7 ]
Laurent-Puig, P. [6 ]
Ychou, M. [8 ]
机构：
[1] CRLC Val dAurelle, Stat, Montpellier 5, France
[2] CHU Robert Debre, Reims, France
[3] Ctr Antoine Lacassagne, F-06054 Nice, France
[4] Ctr Oscar Lambret, F-59020 Lille, France
[5] Ctr Rene Gauducheau, F-44035 Nantes, France
[6] Hop Georges Pompidou, APHP, Paris 15, France
[7] Ctr Leon Berard, F-69373 Lyon, France
[8] CRLC Val dAurelle, Oncol, Montpellier 5, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71736-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [31] UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (pts) with non resectable metastatic colorectal cancer(MCRC): Results of two multicentric phase II trials.
    Douillard, JY
    Bennouna, J
    Artru, P
    Perrier, H
    Paillot, B
    Husseini, F
    Priou, F
    Imadalou, K
    Delord, JP
    Bugat, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [32] A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation
    Lenz, Heinz-Josef
    Ahn, Daniel H.
    Ridinger, Maya
    Erlander, Mark G.
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [33] Interim analysis of a multicentre phase II trial evaluating cetuximab in combination with folfirinox (LV5FU+CPT-11+LOHP) as first line treatment of metastatic colorectal cancer (MCRC) patients
    Samalin, E.
    Thezenas, S.
    Mineur, L.
    Viret, F.
    Assenat, E.
    Senesse, P.
    Bleuse, J.
    Kramar, A.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 86 - 86
  • [34] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [35] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) IN METASTATIC COLORECTAL CANCER (MCRC): UPDATED RESULTS OF A PHASE II GONO TRIAL
    Vasile, Enrico
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cupini, Samanta
    Di Marsico, Roberta
    Antonuzzo, Andrea
    Baldi, Giacomo Giulio
    Stasi, Irene
    Pfanner, Elisabetta
    Ciarlo, Andrea
    Del Monte, Francesca
    Conte, Davide
    Iacovelli, Roberto
    Sonaglio, Claudia
    Granetto, Cristina
    Donati, Sara
    Andreuccetti, Michele
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2009, 20
  • [36] Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II GONO trial
    Masi, G.
    Salvatore, L.
    Fornaro, L.
    Vasile, E.
    Baldi, G. G.
    Stasi, I.
    Ciarlo, A.
    Tuzi, A.
    Andreuccetti, M.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 346 - 346
  • [37] Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer. Results of a two-cohort multicenter phase II trial
    Niederle, N.
    Freier, P.
    Porschen, R.
    Arnold, D.
    Lordick, F.
    Hoehler, T.
    Kubicka, S.
    Kettnera, E.
    Keilholz, U.
    Schmoll, H.-J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 184 - 184
  • [38] Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.
    Bazarbashi, S.
    Aljubran, A. H.
    Soudy, H.
    Darwish, A.
    Eltigani, A.
    Nabil-Ahmed, M.
    Edesa, W.
    Almubarak, M.
    Abu Sabaa, A.
    Shoukri, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [40] Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102
    Chiorean, E. Gabriela
    Picus, Joel
    Breen, Timothy
    Ansari, Rafat H.
    Harb, Wael A.
    Burns, Matthew
    Spittler, Aaron John
    Loehrer, Patrick J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345